For General Information, page-2737

From the Market Herald report in June

Antisense Therapeutics (ANP) announces positive results from its first animal study of its ATL1102 treatment against limb-girdle muscular dystrophy R2 (LGMDR2)As part of the study, ANP treated mice that had the rare disease with ATL1102 at three different dose levelsThe results show that the lowest dose of the treatment brought about a “significant” decrease in the RNA levels of some key immune cells in the quadriceps muscle. This essentially means Antisense will now progress its study to a second phase, slated for later this year, to test its product’s ability to reduce fat levels, muscle loss and damage.

James said at the meeting the second phase data for limb girdle will be released very soon. So I assume
they are testing ability to reduce fat levels, muscle loss and damage..